157 related articles for article (PubMed ID: 20095432)
21. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.
Hausman SZ; Burns DL
Infect Immun; 2000 Jun; 68(6):3763-7. PubMed ID: 10816544
[TBL] [Abstract][Full Text] [Related]
22. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model.
Skerry CM; Mahon BP
Clin Vaccine Immunol; 2011 Feb; 18(2):187-93. PubMed ID: 21147936
[TBL] [Abstract][Full Text] [Related]
23. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.
Mielcarek N; Riveau G; Remoué F; Antoine R; Capron A; Locht C
Nat Biotechnol; 1998 May; 16(5):454-7. PubMed ID: 9592394
[TBL] [Abstract][Full Text] [Related]
24. Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.
Kamachi K; Arakawa Y
Vaccine; 2007 Jan; 25(6):1000-6. PubMed ID: 17050047
[TBL] [Abstract][Full Text] [Related]
25. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.
Jahnmatz M; Amu S; Ljungman M; Wehlin L; Chiodi F; Mielcarek N; Locht C; Thorstensson R
Vaccine; 2014 Jun; 32(27):3350-6. PubMed ID: 24793938
[TBL] [Abstract][Full Text] [Related]
26. DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.
Kamachi K; Konda T; Arakawa Y
Vaccine; 2003 Nov; 21(31):4609-15. PubMed ID: 14575775
[TBL] [Abstract][Full Text] [Related]
27. [Antigenic variability of Bordetella pertussis strains isolated in 1967-2010 in the Czech Republic--possible explanation for the rise in cases of pertussis?].
Zavadilová J; Lžičařová D; Musílek M; Křížová P; Fabiánová K
Epidemiol Mikrobiol Imunol; 2015 Sep; 64(3):130-8. PubMed ID: 26448300
[TBL] [Abstract][Full Text] [Related]
28. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C
Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998
[TBL] [Abstract][Full Text] [Related]
29. Cross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines.
Sukumar N; Sloan GP; Conover MS; Love CF; Mattoo S; Kock ND; Deora R
Infect Immun; 2010 May; 78(5):2008-16. PubMed ID: 20176797
[TBL] [Abstract][Full Text] [Related]
30. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis.
Reveneau N; Alonso S; Jacob-Dubuisson F; Mercenier A; Locht C
Vaccine; 2001 Dec; 20(5-6):926-33. PubMed ID: 11738759
[TBL] [Abstract][Full Text] [Related]
31. The advent of recombinant pertussis vaccines.
Burnette WN
Biotechnology (N Y); 1990 Nov; 8(11):1002-5. PubMed ID: 1366927
[No Abstract] [Full Text] [Related]
32. Genetic Variation of Bordetella pertussis in Austria.
Wagner B; Melzer H; Freymüller G; Stumvoll S; Rendi-Wagner P; Paulke-Korinek M; Repa A; Mooi FR; Kollaritsch H; Mittermayer H; Kessler HH; Stanek G; Steinborn R; Duchêne M; Wiedermann U
PLoS One; 2015; 10(7):e0132623. PubMed ID: 26182210
[TBL] [Abstract][Full Text] [Related]
33. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates.
Gzyl A; Augustynowicz E; Gniadek G; Rabczenko D; Dulny G; Slusarczyk J
Vaccine; 2004 Jun; 22(17-18):2122-8. PubMed ID: 15149768
[TBL] [Abstract][Full Text] [Related]
34. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model.
Kavanagh H; Noone C; Cahill E; English K; Locht C; Mahon BP
Clin Exp Allergy; 2010 Jun; 40(6):933-41. PubMed ID: 20184606
[TBL] [Abstract][Full Text] [Related]
35. Bordetella pertussis, B. parapertussis, vaccines and cycles of whooping cough.
Bouchez V; Guiso N
Pathog Dis; 2015 Oct; 73(7):. PubMed ID: 26242280
[TBL] [Abstract][Full Text] [Related]
36. [Cellular and acellular anti-pertussis vaccines].
Locht C
Ann Pharm Fr; 2001 May; 59(3):198-205. PubMed ID: 11427821
[TBL] [Abstract][Full Text] [Related]
37. Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models.
Li R; Cheng C; Chong SZ; Lim AR; Goh YF; Locht C; Kemeny DM; Angeli V; Wong WS; Alonso S
Allergy; 2012 Oct; 67(10):1250-8. PubMed ID: 22909095
[TBL] [Abstract][Full Text] [Related]
38. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
[TBL] [Abstract][Full Text] [Related]
39. Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice.
Mallaley PP; Halperin SA; Morris A; MacMillan A; Lee SF
Can J Microbiol; 2006 May; 52(5):436-44. PubMed ID: 16699568
[TBL] [Abstract][Full Text] [Related]
40. Is there a need for a new generation of vaccines against pertussis?
Storsaeter J; Wolter J
Expert Opin Emerg Drugs; 2006 May; 11(2):195-205. PubMed ID: 16634696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
